Research letter
Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed

https://doi.org/10.1016/j.jaad.2019.05.007Get rights and content

First page preview

First page preview
Click to open first page preview

References (4)

There are more references available in the full text version of this article.

Cited by (37)

  • Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis

    2021, Journal of the American Academy of Dermatology
    Citation Excerpt :

    Forty-seven studies were full-text reviewed; 14 unique studies were included comprising 655 patients with psoriasis (Supplemental Fig 1; available via Mendeley at https://doi.org/10.17632/5z29m63xpz.1).17,35-46 One study reported on only secukinumab,35 10 studies reported on only ixekizumab,17,36-44 2 studies reported on only brodalumab,45,46 and 1 study reported on all treatments47 (Supplemental Table I; available via Mendeley at https://doi.org/10.17632/5z29m63xpz.1). Four studies reported the time between switches, 3 reported on the minimum washout period between switches, and 7 reported no information on the time between switches.

View all citing articles on Scopus

Funding sources: This study received funding from Ortho Dermatologics.

Conflicts of interest: Dr Kimmel participated on an advisory board for Ortho Dermatologics, October 2018. Dr Chima is a consultant for Leo Pharma. Dr Bagel is an investigator, speaker, or advisory board for LEO, Abbvie, Amgen, Eli-Lilly, Novartis, Celgene, Janssen, Boehringer Ingelheim, BMS, and UCB. Dr Lebwohl receives research funds from Abbvie, Amgen, Arcutis, AstraZeneca, Boehringer Ingelheim, Celgene, Clinuvel, Corrona, Inc, Eli Lilly, Foundation for Research & Education in Dermatology, Incyte, Janssen Research & Development, LLC,Kadmon Corp, LLC, Leo Pharmaceuticals, MedImmune, Novartis, Ortho Dermatologics, Pfizer, Sciderm, UCB, Inc, and ViDac and is a consultant for Allergan, Almirall, Arcutis Inc, Boehringer Ingelheim, Bristol-Myers Squibb, Castle Biosciences, Leo Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy's Laboratories, Theravance, and Verrica. Drs H. Kim, Bares, and S. Kim, and Christopher J. Yao, and Giselle Singer have no conflicts of interest to declare.

View full text